Acute Lymphoblastic Leukemia: Pharmacologic Management
Acute lymphoblastic leukemia (ALL) is the most prevalent pediatric leukemia and makes up one-quarter of cancer cases among adolescents and children younger than 15 years.
Cancer Management
Cancer Therapy Advisor’s cancer treatment resources now include the most recent guideline-based information to inform oncologists and oncology professionals about therapy selection for optimal patient outcomes. These articles provide accurate and up-to-date information about FDA-approved therapies commonly recommended in cancer treatment guidelines for different types of cancer, recent updates to US guidelines for cancer treatment, and adverse events and drug-drug interactions associated with certain therapies.
Sign up for the Cancer Therapy Advisor newsletter to stay up to date.
The CTA newsletter arrives in your inbox daily with the most current news and information on cancer research, new drugs for treatment, and helpful resources for clinicians.
Acute Myeloid Leukemia: Pharmacologic Management
Acute myeloid leukemia (AML) is the most prevalent adult acute leukemia. According to the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, as many as 20,380 cases of AML will be diagnosed in 2023.
Adult T-Cell Lymphoma: Pharmacologic Management
Adult T-cell lymphoma is a rare type of non-Hodgkin lymphoma (NHL) that affects T lymphocytes and natural killer (NK) cells. They are a group of heterogeneous malignancies that account for 12% of all NHL cases
Anal Cancer: Pharmacologic Management
Anal cancer, of which fewer than 10,000 patients are diagnosed annually in the United States, is an uncommon type of cancer occurring in the tissue of the anus.
Biliary Tract Cancers: Pharmacologic Management
Biliary tract cancers are a rare but deadly form of cancer that account for 2% to 3% of all malignancies in the United States. Biliary tract cancer typically presents between the ages of 60 and 70 years.
Bladder Cancer Guidelines
The best bladder cancer treatment option may include more than one type or combination of different treatments (chemotherapy, radiation, and surgery).
Bladder Cancer: Pharmacologic Management
Bladder cancer is the sixth most prevalent cancer in the United States. As of 2023, 82,290 new diagnoses of bladder cancer (62,420 in men and 19,870 in women) were documented, as well as 16,710 deaths.
Bone Cancer: Pharmacologic Management
Primary bone cancers are rare cancers that arise from primitive mesenchymal cells from which all connective tissues are derived. Bone cancer accounts for 0.2% of all cancers.
Brain Cancer: Pharmacologic Management
Glioblastoma multiforme (GBM) is the most malignant and frequently diagnosed primary brain tumor, accounting for more than 60% of all brain cancer diagnoses in adults.
Breast Cancer: Pharmacologic Management
The National Cancer Institute estimates that there will be 297,790 new cases of invasive breast cancer and 55,720 new cases of ductal carcinoma in situ (DCIS) diagnosed in 2023.
Colon Cancer Guidelines
Colon cancer is the third most common cancer diagnosed in the United States. The overall lifetime risk of developing colorectal cancer is approximately 1 in 23 for men and 1 in 25 in women. Learn more about the staging, management, and prognosis of colon cancer.
Colorectal Cancer: Pharmacologic Management
Colorectal cancer is the third most common cancer and the second leading cause of cancer death in the United States.1 Colorectal cancer is an umbrella term that refers to cancer of both the colon and the rectum.
Chronic Lymphocytic Leukemia: Pharmacologic Management
The American Cancer Society estimates that fewer than 19,000 patients will develop CLL and approximately 4500 patients will die from the hematologic malignancy in 2023.
Cervical Cancer: Pharmacologic Management
Cervical cancer is the fourth most common cancer in women worldwide, with 604,000 new cases reported in 2020. In 2023, an estimated 13,960 new cases of cervical cancer will be diagnosed, and 4310 deaths will be attributed to the malignancy in the United States.
Chronic Myeloid Leukemia: Pharmacologic Management
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a hematologic malignancy that arises from dysregulation of hematopoietic stem cells in the bone marrow (myeloproliferative neoplasm).
Endometrial Cancer: Pharmacologic Management
Endometrial cancer is the most common type of gynecologic cancer in the United States, with approximately 66,000 new cases diagnosed in 2023.
Esophageal Cancer: Pharmacologic Management
Esophageal cancer accounts for 1.1% of all cancer cases and is the 11th leading cause of cancer death in the United States.
Follicular Lymphoma: Pharmacologic Management
Follicular lymphoma makes up approximately 20% of all non-Hodgkin lymphoma diagnoses and is the second-most common type of slow-growing lymphoid malignancy in western countries.
Gastric Cancer: Pharmacologic Management
Gastric cancer is the fifth most common malignant cancer and the fourth leading cause of cancer-related mortality globally.
Head and Neck Cancer: Treatment & Management
Head and neck cancer is the seventh most common cancer worldwide2 and accounts for approximately 4% of all cancers in the United States.
Hepatocellular Carcinoma: Pharmacologic Management
Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer worldwide, accounting for approximately 75% of liver cancer diagnoses.
Hodgkin Lymphoma: Pharmacologic Treatment
Hodgkin lymphoma (formerly known as Hodgkin’s disease) is a rare type of lymphoma that accounts for only 0.5% of all new cancer cases in the United States.
Melanoma: Pharmacologic Management
Melanoma is a cancer that affects the melanocytes located in the skin (cutaneous) and neural crest cells located in the uveal tract of the eyes.
Mesothelioma: Pharmacologic Management
Malignant mesothelioma is a rare cancer that arises from mesothelial cells; it occurs most commonly in the pleura and peritoneum but is also known to cause primary tumors in the testes and heart.
Metastatic Breast Cancer: Pharmacologic Management
Breast cancer is the most common type of cancer, with an estimated 300,590 new cases in the United States in 2023. The National Cancer Institute also estimates that breast cancer will account for 43,170 to 43,530 new deaths in 2023.
Multiple Myeloma: Pharmacologic Management
Multiple myeloma is a malignancy of the plasma cells. Multiple myeloma develops when clonal plasma cells proliferate in the bone marrow or form extramedullary plasmacytomas.
Myelodysplastic Syndrome: Pharmacologic Management
Myelodysplastic syndrome (MDS) represents a group of conditions that result from blood-forming stem cells in the bone marrow failing to mature properly into healthy blood cells.
Non-Hodgkin Lymphoma: Pharmacologic Management
Non-Hodgkin lymphoma (NHL) consists of a diverse group of lymphomas that originate in the lymphoid tissues and spread throughout the body.
Non-Small Cell Lung Cancer: Pharmacologic Treatment
Lung cancer is the second most common cancer in the United States and estimated to account for 12.2% of new cancer cases in 2023.
Ovarian Cancer: Pharmacologic Treatment
Among gynecologic cancers, ovarian cancer is associated with the most deaths and is the fifth most frequent cause of death overall in women.
Pancreatic Cancer: Pharmacologic Management
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent pancreatic malignancy. This condition represents approximately 3% of all cancers in the United States and approximately 7% of all cancer deaths.
Peripheral T-Cell Lymphoma: Pharmacologic Management
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of cancers that affect mature T cells. They fall under the umbrella of non-Hodgkin lymphoma, which is anticipated to account for 4.1% of new cancer cases in 2023.
Pheochromocytoma Diagnosis & Treatment
Pheochromocytoma is a rare neuroendocrine disorder in which a tumor grows within the adrenal medulla. This tumor causes the continuous overproduction of epinephrine and norepinephrine, which, if left without treatment, can lead to severe or life-threatening damage to other body systems.
Pituitary Adenoma and Pregnancy
Pituitary adenomas are typically prolactinomas, which are the most frequent cause of elevated prolactin levels. Pituitary adenomas comprise over 85% of pituitary tumors, and 25% to 30% of these are hormonally inactive. The incidence of prolactinomas is four times greater in women than in men.
Prostate Cancer Guidelines
Prostate cancer is the second most common type of cancer, and cancer death, in men in the United States with an estimated annual incidence of 268,490 cases and an estimated 34,500 deaths each year.
Prostate Cancer: Pharmacologic Management
In the United States, prostate cancer is the most frequent cancer diagnosed in men and the second most common cause of cancer fatalities.
Renal Cell Carcinoma Guidelines
Renal Cell Carcinoma is the 10th most common cancer. Most renal cancers arise from the epithelial tubules of the nephron. This reference covers risk factors, testing, prognosis, and treatments.
Renal Cell Carcinoma: Pharmacologic Management
Renal cell carcinoma (RCC) is the most prevalent type of kidney cancer, accounting for approximately 90% of all cases.
Small Cell Lung Cancer: Pharmacologic Management
Small cell lung cancer (SCLC) accounts for approximately 14% of lung and bronchus cancers, with approximately 30,000 to 35,000 new cases diagnosed in the United States each year.
Testicular Cancer: Pharmacologic Management
Testicular cancer is the most common solid tumor diagnosed in US men aged 20 to 34 years,1 and it is diagnosed with decreasing frequency as men age.
Thymoma: Pharmacological Management
Thymoma is a thymus gland cancer that is a type of thymic epithelial tumor, which also includes thymic carcinoma and neuroendocrine tumors (NETs).
Thyroid Cancer: Pharmacologic Management
Thyroid cancer — a malignancy affecting the thyroid gland, which is located in the front of the throat — occurs more frequently in women than men. Patients are often diagnosed with thyroid cancer at a younger age compared with most other cancers.
Uterine Sarcoma: Pharmacologic Management
Uterine sarcoma is a rare type of uterine cancer that makes up less than 1% of all gynecologic malignancies and only 2% to 5% of uterine malignancies. In the United States, uterine carcinoma has an annual incidence of 0.36 to 0.64 cases per 100,000 women.
Waldenström Macroglobulinemia: Pharmacologic Management
Waldenström macroglobulinemia (WM) is a subtype of lymphoplasmacytic lymphoma (LPL), a rare type of non-Hodgkin lymphoma (NHL). WM results from the accumulation of immunoglobulin M (IgM) antibodies in the blood and lymphoplasmacytic cells in the bone marrow.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...